EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Biodegradable Nanocarriers for Sustained Release of Antidiabetic Drugs

Farah Nadia Azman, Wei Loong Chen

Emerging Pharmaceutical Sciences and Innovation · 27.09.2026 · 1 (1)

DOI: 10.53623/epsi.v1i1.1315 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Emerging Pharmaceutical Sciences and Innovation, online erschienen am 27.09.2026. Verfasst von Farah Nadia Azman und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of diabetes mellitus relies heavily on antidiabetic agents – insulin, sulfonylureas, biguanides, and incretin-based peptides – whose conventional dosage forms are frequently limited by short plasma half-life, enzymatic degradation, poor membrane permeability, and the need for frequent dosing, all of which compromise sustained glycemic control and patient adherence. Biodegradable nanocarriers constructed from polyesters (poly(lactic-co-glycolic acid), polylactic acid, polycaprolactone) and natural biopolymers (chitosan, alginate, xanthan gum) have emerged as a mechanistically coherent strategy to overcome these limitations by protecting labile antidiabetic actives, prolonging systemic or mucosal residence, and enabling programmable, sustained drug release as the carrier undergoes hydrolytic or enzymatic biodegradation. This review comparatively examines conventional and biodegradable nanocarrier-based delivery of representative antidiabetic drugs – insulin, glibenclamide, gliclazide, glipizide, and metformin – across physicochemical, sustained-release, pharmacodynamic, and safety dimensions. Across the reviewed literature, biodegradable nanocarrier encapsulation consistently improved encapsulation efficiency, prolonged and pH-responsive drug release, and produced more stable glycemic control in preclinical models relative to conventional dosage forms. However, incomplete characterization of polymer biodegradation kinetics, nanotoxicological uncertainty, and the absence of harmonized regulatory pathways continue to constrain clinical translation. We conclude that biodegradable nanocarriers represent an empirically supported route to achieve sustained-release antidiabetic therapy, provided that standardized biodegradation characterization, robust safety evaluation, and harmonized regulatory frameworks are developed in parallel.

Zitieren

APA

Azman, F. N., & Chen, W. L. (2026). Development of Biodegradable Nanocarriers for Sustained Release of Antidiabetic Drugs. Emerging Pharmaceutical Sciences and Innovation, 1(1). https://doi.org/10.53623/epsi.v1i1.1315

Vancouver

Azman FN, Chen WL. Development of Biodegradable Nanocarriers for Sustained Release of Antidiabetic Drugs. Emerging Pharmaceutical Sciences and Innovation. 2026;1(1). doi:10.53623/epsi.v1i1.1315

BibTeX
@article{Azman2026,
  author = {Azman, Farah Nadia and Chen, Wei Loong},
  title = {Development of Biodegradable Nanocarriers for Sustained Release of Antidiabetic Drugs},
  journal = {Emerging Pharmaceutical Sciences and Innovation},
  year = {2026},
  volume = {1},
  number = {1},
  doi = {10.53623/epsi.v1i1.1315}
}
Kostenlos starten →